328 filings
ARS
2023 FY
ADAP
Adaptimmune Therapeutics Plc
22 Apr 24
Annual report to shareholders
5:15pm
8-K
ADAP
Adaptimmune Therapeutics Plc
12 Apr 24
Company remains focused on launching afami-cel later this year with a PDUFA date of August 4th and developing its broader sarcoma franchise
8:05am
DEF 14A
ADAP
Adaptimmune Therapeutics Plc
Definitive proxy
11 Apr 24
8:00am
PRE 14A
ADAP
Adaptimmune Therapeutics Plc
Preliminary proxy
1 Apr 24
8:01am
10-K
2023 FY
ADAP
Adaptimmune Therapeutics Plc
Annual report
6 Mar 24
7:12am
8-K
8w5lw bz6axextdg
6 Mar 24
Adaptimmune Reports Q4 /Full Year 2023 Financial Results and Business Updates
7:05am
8-K
pe0he
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
8-K
nxau0 sn18np
16 Feb 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm
8-K
y57ylp02hmaslf7 op
31 Jan 24
Other Events
5:07pm
8-K
yydu4y4
4 Jan 24
Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million – Presentation at JP Morgan Healthcare Conference
7:46am
8-K
ld4 b2tpf7rnl1gzaxt
6 Dec 23
Other Events
7:13am
S-8
l35n5trisuj2uj245llt
30 Nov 23
Registration of securities for employees
4:16pm
8-K
hqii u6btl0
14 Nov 23
Other Events
12:00am
8-K
oolvs4
8 Nov 23
Adaptimmune Reports Third Quarter Financial Results and Business Update
7:37am
8-K
vaja2h
3 Nov 23
Departure of Directors or Certain Officers
4:15pm
8-K
9t9t tiwb
31 Oct 23
Adaptimmune Reports Positive Data with Lete-cel1 from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
8:07am
8-K
tjsr82t
31 Aug 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:19pm
8-K/A
ajqbbno8wi1svlbm1mlx
10 Aug 23
Financial Statements and Exhibits
4:05pm